Literature DB >> 31402498

Regulation of immune system development and function by Cbl-mediated ubiquitination.

Xin Li1, Liying Gong2,3, Hua Gu2,3,4.   

Abstract

Ubiquitination is a form of posttranslational protein modification that affects the activity of target proteins by regulating their intracellular degradation, trafficking, localization, and association with other regulators. Recent studies have placed protein ubiquitination as an important regulatory mode to control immune system development, function, and pathogenesis. In this review, we will mainly update the research progress from our laboratory on the roles of the Cbl family of E3 ubiquitin ligases in the development and function of lymphocytes and non-lymphoid cells. In addition, we will highlight our current understanding of the mechanisms used by this family of proteins, especially Cbl and Cbl-b, to co-ordinately regulate the function of various receptors and transcription factors in the context of immune regulation and diseases.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Cbl and Cbl-b; T and B cells; germinal center; lymphocyte development; ubiquitination

Mesh:

Substances:

Year:  2019        PMID: 31402498     DOI: 10.1111/imr.12789

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  10 in total

Review 1.  Multifaceted Roles of the E3 Ubiquitin Ligase RING Finger Protein 115 in Immunity and Diseases.

Authors:  Mei-Xia Wang; Tianzi Liuyu; Zhi-Dong Zhang
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

2.  Chromatin Priming Renders T Cell Tolerance-Associated Genes Sensitive to Activation below the Signaling Threshold for Immune Response Genes.

Authors:  Sarah L Bevington; Sky T H Ng; Graham J Britton; Peter Keane; David C Wraith; Peter N Cockerill
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

Review 3.  Roles of Ubiquitination and Deubiquitination in Regulating Dendritic Cell Maturation and Function.

Authors:  Bo Zhu; Lihua Zhu; Lin Xia; Yuyun Xiong; Qing Yin; Ke Rui
Journal:  Front Immunol       Date:  2020-11-16       Impact factor: 7.561

Review 4.  Targeting ubiquitin signaling for cancer immunotherapy.

Authors:  Xiaofei Zhou; Shao-Cong Sun
Journal:  Signal Transduct Target Ther       Date:  2021-01-13

5.  Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions.

Authors:  Marion Buffard; Aurélien Naldi; Gilles Freiss; Marcel Deckert; Ovidiu Radulescu; Peter J Coopman; Romain M Larive
Journal:  Biomolecules       Date:  2021-02-18

Review 6.  Targeting neddylation E2s: a novel therapeutic strategy in cancer.

Authors:  Yi-Chao Zheng; Yan-Jia Guo; Bo Wang; Chong Wang; M A A Mamun; Ya Gao; Hong-Min Liu
Journal:  J Hematol Oncol       Date:  2021-04-07       Impact factor: 17.388

7.  Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.

Authors:  Walter J Storkus; Deena Maurer; Yan Lin; Fei Ding; Anamika Bose; Devin Lowe; Amy Rose; Melissa DeMark; Lilit Karapetyan; Jennifer L Taylor; Manoj Chelvanambi; Ronald J Fecek; Jessica N Filderman; Timothy J Looney; Lauren Miller; Elizabeth Linch; Geoffrey M Lowman; Pawel Kalinski; Lisa H Butterfield; Ahmad Tarhini; Hussein Tawbi; John M Kirkwood
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 12.469

Review 8.  Current methodologies in protein ubiquitination characterization: from ubiquitinated protein to ubiquitin chain architecture.

Authors:  Mingwei Sun; Xiaofei Zhang
Journal:  Cell Biosci       Date:  2022-08-12       Impact factor: 9.584

Review 9.  Current Challenges in Vaccinology.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Peter Palese; Gregory A Poland
Journal:  Front Immunol       Date:  2020-06-25       Impact factor: 7.561

10.  Cbls boost B cells.

Authors:  Michelle A Linterman
Journal:  J Exp Med       Date:  2020-09-07       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.